Targeted multiplex proteomics for the development and validation of biomarkers in primary aldosteronism subtyping
Authors' conclusion
The new blood-based biomarkers for PA subtyping hold the potential to significantly enhance clinical utility and advance the practice of PA care.
Study context
- Population
- Patients with primary aldosteronism (PA) (aldosterone-producing adenomas (APA) or bilateral hyperaldosteronism (BHA)) and essential hypertension
- Comparison
- Five-protein panel plus aldosterone and renin vs Kobayashi score for PA subtyping
- Outcome
- Differentiation of APA from BHA by blood-based proteomic biomarkers
Methodological detailstargeted multiplex proteomics, biomarker development and validation
- Targeted multiplex proteomics
- Biomarker development and validation
Performance
As reported in the abstract
Blood-based prediction (five protein biomarkers with aldosterone and renin)
AUC, essential hypertension vs PA
0.986
95% CI 0.963–1.000
AUC, subtyping APA vs BHA
0.922
95% CI 0.846–0.998
Further findings
Five-protein panel in tissue and blood
- Five-protein panel highly effective in distinguishing APA from BHA in both tissue and blood samples
Differential pathways
- Differential pathways associated with PA pathophysiology validated, aligning with current knowledge
Original publication
Targeted multiplex proteomics for the development and validation of biomarkers in primary aldosteronism subtyping. Eur J Endocrinol. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →